211At-BC8-B10

N/A

Report date: 2025/09/12 20:01:19

Base Information

Drug Name211At-BC8-B10
Drug Alias Name211At-Labeled Anti-CD45 MAb BC8-B10211At-BC8-B10
ClassificationRadiation-emitting products > Nuclides > Astatine > 211AtRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive therapeutic agent +[4
Mechanisms of ActionAnti-CD45
TargetsLeukocyte common antigen
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLymphoma +[8
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLymphoma +[8
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A